Table 3.
Prior trials with BRCA1 and BRCA2 mutation carrier outcomes
| Study | N | Survival results | p-value (reported) | |
|---|---|---|---|---|
| Pharoah, 1999 | BRCA1 | 127 | Median survival: 20.6 mo 5-yr OS 21% (95% CI 14–28) |
NS |
| BRCA2 | 24 | Median survival: 16.0 mo 5-yr OS 25% (95% CI 8–42) |
||
| Boyd, 2000† | BRCA1 | 67 | 5-yr OS ~45% | -- |
| BRCA2 | 21 | 5-yr OS ~47% | ||
| Ramus, 2001 | BRCA1 | 15 14 185 delAG 1 5382insC |
Median survival: 52 mo (95% CI 25–79) | NS |
| BRCA2 | 12 all 6174delT |
Median survival: 49 mo (95% CI 24–73) | ||
| Ben David, 2002 | BRCA1 | 171 152 185delAG 19 5382insC |
Median survival: 185delAG: 52 mo (95% CI 41–63) 5382insC: >72 mo (95% CI NA) |
NS |
| BRCA2 | 58 all 6174delT |
Median survival: 52 mo (95% CI 34-NA) | ||
| Cass, 2003‡ | BRCA1 | 22 | Disease-free interval: 40 mo | 0.2 |
| BRCA2 | 12 | Disease-free interval: 57 mo | ||
| Pal, 2007 | BRCA1 | 20 | 4-yr OS 37% | 0.355 |
| BRCA2 | 12 | 4-yr OS 83% | ||
| Chetrit, 2008‡ | BRCA1 | 203 141 185delAG 18 5382insC |
Median survival: 45.1 mo (95% CI 38.8–52.4) | 0.2 |
| BRCA2 | 54 all 6174delT |
Median survival: 52.5 mo (95% CI 38.7–82.6) | ||
| Vencken, 2011 | BRCA1 | 99 | Median survival: 5.9 yrs 5-yr OS 60% |
0.06 (for OS) |
| BRCA2 | 13 | Median survival: >10 yrs 5-yr OS 85% |
†
Overall survival is estimated graphically from survival curves
‡
Survival results based on advanced-stage patients only
References:
- Pharoah PDP, Easton DF, Stockton DL, Gayther S, Ponder BAJ, Group UFOCS. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Res 1999;59: 868–871.
- Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, Saigo PE, Almadrones LA, Barakat RR, Brown CL, Chi DS, Curtin JP, Poynor EA, Hoskins WJ. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283: 2260–2265.
- Ramus SJ, Fishman A, Pharoah PD, Yarkoni S, Altaras M, Ponder BA. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur J Surg Oncol 2001;27: 278–81.
- Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, Ben-Baruch G, Fishman A, Levavi H, Lubin F, Menczer J, Piura B, Struewing JP, Modan B. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002;20: 463–6.
- Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97: 2187–95.
- Pal T, Permuth-Wey J, Kapoor R, Cantor A, Sutphen R. Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer 2007;6: 113–9.
- Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The National Israeli Study of Ovarian Cancer. J Clin Oncol 2008;26: 20–25.
- Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, Hooning MJ, Berns EM, Jager A, Collee M, Burger CW, Seynaeve C. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 2011;12: 12.